- Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda<p>Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillio…BioPharma Dive · 1mo ago↗ source
- On second try, Acadia drug gets nod from European regulators<figure><div><img src="https://imgproxy.divecdn.com/HqB6XqxuaD9NspfVrU6NR4gdT5eCkfyQMHS0wCYOdwk/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjU1OTk4NTE0LmpwZ…BioPharma Dive · 1mo ago↗ source
- Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and moreWelcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will reach its maximum tilt toward the sun at 4:24 a.m. Eastern time on Sunda…